Results 131 to 140 of about 24,933,173 (248)

Dual biologic therapy in inflammatory bowel disease, a retrospective cohort study of vedolizumab and anti‐tumor necrosis factor alpha therapy in children

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Despite advances in pediatric inflammatory bowel disease (PIBD) with biologics, remission rates remain at 47%–60% with loss‐of‐response rates at 60%–68%. Evidence for efficacy of dual biologic therapy (DBT) with anti‐tumor necrosis factor alpha therapy (anti‐TNF‐α)‐ vedolizumab (VDZ) for children refractory to anti‐TNF‐α therapy is ...
Jonathan E. M. O'Donnell, Carlie Bolles, Claire R. Reilly, Manal Morgan, Christopher Burgess, Fariha Balouch, Peter J. Lewindon   +6 more
wiley   +1 more source

A consensus-based treatment algorithm for alopecia areata in adolescents and adults: integrating severity, quality of life, and disease dynamics

Frontiers in Medicine
IntroductionAlopecia areata (AA) is an autoimmune, inflammatory condition characterized by non-scarring hair loss on the scalp, face, or body. It can significantly affect a person’s quality of life (QoL) and mental health.MethodsUsing a modified Delphi ...
Charles W. Lynde, Lyn Guenther, Anneke Andriessen, Sameh Hanna, Elena Netchiporouk, Vimal Prajapati, Vimal Prajapati, Marni Wiseman, Marni Wiseman, Julien Ringuet, Julien Ringuet   +10 more
doaj   +1 more source

Age- and gender-based frequency and association of common myeloproliferative mutations in a South African cohort

African Journal of Laboratory Medicine
Background: Age, gender, and mutation type are key risk factors for myeloproliferative neoplasms (MPNs). Africa remains under-represented in global cancer statistics due to limited population-based genomic data.
Bathabile Mbele, Kapila Bhowan, Brendon Roets   +2 more
doaj   +1 more source

A systematic literature review of Janus kinase inhibitors for the treatment of systemic sclerosis

OBJECTIVES: The use of Janus kinase inhibitors is increasing in systemic sclerosis, a complex autoimmune disease characterized by fibrosis, vasculopathy, and immune dysregulation.
Sener, Seher, Sener, Yusuf Ziya, Sari, Alper, Batu, Ezgi Deniz, Akdogan, Ali   +4 more
core   +1 more source

The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Infantile‐onset inflammatory bowel disease (IOIBD) is a rare and severe subset of very‐early‐onset IBD, often associated with immune dysregulation and poor response to conventional therapies. Data regarding the use of Janus kinase inhibitors (JAKI) in this population is limited.
Smridhi Mahajan, Christian Wysocki, Bhaskar Gurram   +2 more
wiley   +1 more source

Advancing therapeutic frontiers: a pipeline of novel drugs for UC management

Frontiers in Gastroenterology
Ulcerative colitis is a chronic inflammatory bowel disease with rising global prevalence. Despite therapeutic advances including biologic agents targeting tumor necrosis factor-alpha, integrins, and interleukin pathways, alongside Janus kinase inhibitors
Luisa Bertin, Alessandro Massano, Carlo Redavid, Marco Scarpa, Cesare Ruffolo, Imerio Angriman, Andrea Buda, Fabiana Zingone, Brigida Barberio, Edoardo Vincenzo Savarino   +9 more
doaj   +1 more source

Janus Kinase Inhibitors as a Third-Line Therapy for Refractory Endogenous Noninfectious Uveitis. [PDF]

PURPOSE Janus kinase (JAK) inhibitors have recently been used to treat patients with biologic refractory noninfectious uveitis (NIU). This narrative review updates the current evidence relevant for their application in patients with refractory NIU.
Garweg, Justus G, Straessle, Kim A
core   +1 more source

Acneiform eruption associated with Janus kinase inhibitors in pediatric inflammatory bowel disease: Case series and clinical management guidance

JPGN Reports, EarlyView.
Abstract Janus kinase inhibitors (JAKi) are increasingly used for refractory inflammatory bowel disease (IBD) in pediatric patients but are associated with significant dermatologic adverse effects. Acneiform eruptions have been reported in up to 30% of adults, with a greater incidence suspected in adolescents.
Tina H. Tran, Daniel Park, Regina‐Celeste Ahmad, Malika Goel, Sofia Verstraete, Sabina Ali   +5 more
wiley   +1 more source

Paradoxical Alopecia Areata Induced by IL‐17 and IL‐23 Inhibitors: A Systematic Review

JEADV Clinical Practice, EarlyView.
This systematic review identifies consistent clinical patterns of alopecia areata associated with IL‐17 and IL‐23 inhibitors, most frequently involving secukinumab and ustekinumab. Disease severity varied widely, and management often required biologic discontinuation or therapeutic switching.
Isabella Kamholtz, Simonetta I. Gaumond, Joaquin J. Jimenez   +2 more
wiley   +1 more source

Role of Plasma Janus Kinase 2 in Assessment of Disease Activity in Ulcerative Colitis

SVU - International Journal of Medical Sciences
Background: Ulcerative colitis (UC) is a chronic autoimmune disease with increasing incidence worldwide. The pathophysiology of UC is multifactorial, including interplay between immune, gut microbiota, genetic vulnerability, and environment-related ...
Asmaa Mahdy Ghaith , Abeer Mahmoud Ibraheem , Ezzat Ali , Fatma Ibrahim Dwedar , Hussien Mahmoud Hussien   +4 more
doaj   +1 more source